drugset / Trial / NCT02138955
A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single center in patient/outpatient, uncontrolled dose escalating study in cancer patients to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of body surface area adjusted doses of liposomal curcumin administered intravenously as an 8 hour infusion once weekly for 8 weeks.
Timeline
- Start
- 2014-03
- Primary completion
- 2017-11-30
- Completion
- 2018-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Curcumin | Small molecule | 300 mg/m2 | Intravenous |
Indications
No indication recorded.